Targeting metabolic transformation for cancer therapy
- PMID: 20300106
- DOI: 10.1038/nrc2817
Targeting metabolic transformation for cancer therapy
Abstract
Cancer therapy has long relied on the rapid proliferation of tumour cells for effective treatment. However, the lack of specificity in this approach often leads to undesirable side effects. Many reports have described various 'metabolic transformation' events that enable cancer cells to survive, suggesting that metabolic pathways might be good targets. There are currently several drugs under development or in clinical trials that are based on specifically targeting the altered metabolic pathways of tumours. This Review highlights pathways against which there are already drugs in different stages of development and also discusses additional druggable targets.
Similar articles
-
Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery.Expert Opin Biol Ther. 2014 Aug;14(8):1145-59. doi: 10.1517/14712598.2014.912270. Epub 2014 Apr 25. Expert Opin Biol Ther. 2014. PMID: 24762115 Review.
-
The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.Mol Aspects Med. 2010 Apr;31(2):145-70. doi: 10.1016/j.mam.2010.02.008. Epub 2010 Mar 2. Mol Aspects Med. 2010. PMID: 20206201 Review.
-
Targeting the molecular basis for tumour hypoxia.Expert Rev Mol Med. 2005 Apr 15;7(6):1-16. doi: 10.1017/S1462399405009117. Expert Rev Mol Med. 2005. PMID: 15831177 Review.
-
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.Drug Resist Updat. 2015 Nov;23:20-54. doi: 10.1016/j.drup.2015.10.003. Epub 2015 Oct 31. Drug Resist Updat. 2015. PMID: 26690339 Review.
-
Use of transcription factors as agents and targets for drug development.Oncology (Williston Park). 1996 Oct;10(10):1532-8; discussion 1541-2. Oncology (Williston Park). 1996. PMID: 8905845 Review.
Cited by
-
Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors.Front Oncol. 2013 May 17;3:117. doi: 10.3389/fonc.2013.00117. eCollection 2013. Front Oncol. 2013. PMID: 23730622 Free PMC article.
-
Intracellular NAD(H) levels control motility and invasion of glioma cells.Cell Mol Life Sci. 2013 Jun;70(12):2175-90. doi: 10.1007/s00018-012-1249-1. Epub 2013 Jan 10. Cell Mol Life Sci. 2013. PMID: 23307072 Free PMC article.
-
Novel and emerging targeted-based cancer therapy agents and methods.Tumour Biol. 2015 Feb;36(2):543-56. doi: 10.1007/s13277-015-3184-x. Epub 2015 Feb 9. Tumour Biol. 2015. PMID: 25663495 Review.
-
Embryonic liver fordin is involved in glucose glycolysis of hepatic stellate cell by regulating PI3K/Akt signaling.World J Gastroenterol. 2016 Oct 14;22(38):8519-8527. doi: 10.3748/wjg.v22.i38.8519. World J Gastroenterol. 2016. PMID: 27784964 Free PMC article.
-
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.Nature. 2013 Jun 6;498(7452):109-12. doi: 10.1038/nature12154. Epub 2013 May 19. Nature. 2013. PMID: 23685455
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources